Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 59% of modeled bridge. Strengths: Bed Count, Commercial Payer %. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $0.1M (vs $0.1M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $35K | $8K | $43K | $0 | 12mo |
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $37K | $37K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $6K | $17K | $22K | $70K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 62.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | $0 | $11K | $22K | $33K | $43K | $43K | $43K | $43K |
| Cost to Collect | $0 | $9K | $18K | $27K | $37K | $37K | $37K | $37K |
| A/R Days Reduction | $0 | $7K | $15K | $22K | $22K | $22K | $22K | $22K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $32K | $64K | $92K | $112K | $112K | $112K | $112K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $112K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 61% / 10.8x | 65% / 12.4x | 69% / 13.9x | 71% / 14.7x | 73% / 15.5x |
| 9.0x | 56% / 9.3x | 60% / 10.7x | 64% / 12.0x | 66% / 12.7x | 68% / 13.4x |
| 10.0x | 52% / 8.0x | 56% / 9.3x | 60% / 10.5x | 62% / 11.1x | 64% / 11.8x |
| 11.0x | 48% / 7.0x | 52% / 8.1x | 56% / 9.3x | 58% / 9.8x | 60% / 10.4x |
| 12.0x | 44% / 6.1x | 48% / 7.2x | 52% / 8.2x | 54% / 8.7x | 56% / 9.3x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 26% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.8x, adding 3.7 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $146K | — | $146K | 8.0% |
| Year 1 | $151K | +$75K | $225K | 12.3% |
| Year 2 | $155K | +$112K | $267K | 14.6% |
| Year 3 | $160K | +$112K | $272K | 14.9% |
| Year 4 | $165K | +$112K | $276K | 15.1% |
| Year 5 | $170K | +$112K | $281K | 15.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Denial Rate Reductio | $22K | $33K | $43K | $52K |
| Cost to Collect | $18K | $27K | $37K | $44K |
| A/R Days Reduction | $11K | $17K | $22K | $27K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $56K | $84K | $112K | $134K |
Peer Context — Where This Hospital Sits
Key metrics vs 61 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | -50.0% | -20.5% | -9.9% | -0.1% | P0 |
| Net-to-Gross | 64.4% | 30.5% | 42.3% | 62.1% | P79 |
| Occupancy | 16.5% | 24.1% | 37.5% | 67.0% | P13 |
| Rev/Bed | $83K | $979K | $2.2M | $3.2M | P2 |
| Exp/Bed | $351K | $1.0M | $2.1M | $3.4M | P3 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.